Importantly, the superior anti-tumor capacity of Ptpn22−/− CD8+ T cells is observed in response to both strong and weak antigens, the latter being a common trait of tumor-associated antigens, which can otherwise limit robust anti-tumor immune responses. Here, CD8A is linked to neoplasm.